Want to see ANIK full AI Analyst Report?
ANIK Stock Chart & Stats
$21.68
$0.07(0.47%)
At close: 4:00 PM EDT
$21.68
$0.07(0.47%)
Day’s Range― - ―
52-Week Range$8.37 - $22.88
Previous Close$15.02
Volume50.57K
Average Volume (3M)123.13K
Market Cap
$281.04M
Enterprise Value$187.52
Total Cash (Recent Filing)$38.41M
Total Debt (Recent Filing)$23.32M
Price to Earnings (P/E)―
Beta0.99
Next Earnings
Oct 29, 2026EPS Estimate
0.24Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.27
Shares Outstanding13,382,966
10 Day Avg. Volume130,091
30 Day Avg. Volume123,127
Financial Highlights & Ratios
PEG Ratio0.16
Price to Book (P/B)0.96
Price to Sales (P/S)1.22
P/FCF Ratio31.59
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$21.00Price Target Upside-3.14% Downside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.12
Revenue Forecast (FY)$118.61M
Bulls Say, Bears Say
Bulls Say
Broad Revenue And Product GrowthGrowth across commercial, international, and core product lines indicates improving demand and a broader revenue base. Continued adoption of CINGAL, MONOVISC, and regenerative products can support durable expansion beyond a single product or market.
Margin And Operating ImprovementHigher gross margins, stronger throughput, improved yields, and lower operating expenses show that operational gains are translating into better economics. These improvements support management’s raised 2026 adjusted EBITDA margin guidance of 13%–17%.
Conservative Balance SheetSubstantial cash and limited leverage provide flexibility to fund capacity expansion, regulatory programs, and product development without relying heavily on external financing. This strengthens resilience while the company works toward consistent profitability.
Bears Say
Persistent Losses And Thin Free Cash FlowDespite improved revenue and operating cash flow, recurring net losses and minimal free cash flow show that earnings quality and cash conversion remain incomplete. Sustained profitability is needed for growth investments to compound without consuming balance-sheet resources.
FDA Approval Risk For HyalofastRegulatory uncertainty can delay U.S. commercialization, limit the product’s contribution to the pipeline, and require additional resources. The removal of expected sales from guidance demonstrates that approval timing remains a material constraint on longer-term growth.
CINGAL Regulatory And Manufacturing RequirementsCINGAL’s drug-combination classification increases development complexity, capital needs, and execution risk. Required manufacturing and CMC investments could extend the path to approval and delay the product’s ability to become a meaningful growth and profit contributor.
Anika Therapeutics News
ANIK FAQ
What was Anika Therapeutics’s price range in the past 12 months?
Anika Therapeutics lowest stock price was $8.37 and its highest was $22.88 in the past 12 months.
What is Anika Therapeutics’s market cap?
Anika Therapeutics’s market cap is $281.04M.
When is Anika Therapeutics’s upcoming earnings report date?
Anika Therapeutics’s upcoming earnings report date is Oct 29, 2026 which is in 54 days.
How were Anika Therapeutics’s earnings last quarter?
Anika Therapeutics released its earnings results on Jul 29, 2026. The company reported $0.42 earnings per share for the quarter, beating the consensus estimate of -$0.08 by $0.5.
Is Anika Therapeutics overvalued?
According to Wall Street analysts Anika Therapeutics’s price is currently Overvalued.
Does Anika Therapeutics pay dividends?
Anika Therapeutics does not currently pay dividends.
What is Anika Therapeutics’s EPS estimate?
Anika Therapeutics’s EPS estimate is 0.24.
How many shares outstanding does Anika Therapeutics have?
Anika Therapeutics has 13,382,966 shares outstanding.
What happened to Anika Therapeutics’s price movement after its last earnings report?
Anika Therapeutics reported an EPS of $0.42 in its last earnings report, beating expectations of -$0.08. Following the earnings report the stock price went up 6.733%.
Which hedge fund is a major shareholder of Anika Therapeutics?
Currently, no hedge funds are holding shares in ANIK
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Anika Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$21.00 (-3.14% Downside)
$21.00 (-3.14% Downside)
Blogger Sentiment
Bullish
ANIK Sentiment 100%
Sector Average 60%
Sector Average 60%
Insider Transactions
Bought Shares
Worth $41.0K over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
128.93%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-2.24%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Anika Therapeutics
Anika Therapeutics, Inc. is a company dedicated to joint preservation, innovating and providing early intervention orthopedic care across the globe, including the United States and Europe. Their core focus areas include osteoarthritis (OA) pain management, regenerative solutions, soft tissue repair, and advanced bone-preserving joint technologies. All of Anika's products are developed, manufactured, and commercialized utilizing their proprietary hyaluronic acid (HA) technology platform. Their comprehensive product lines feature an OA pain management family, which includes established treatments like Monovisc, Orthovisc, Cingal, and Hyvisc, all designed to alleviate discomfort from osteoarthritis. The company's joint preservation and restoration offerings are extensive, comprising approximately 150 bone-sparing joint technology products, alongside solutions for sports medicine soft tissue repair and orthopedic regenerative therapies. Furthermore, Anika leverages its HA expertise in a non-orthopedic product family, developing applications such as adhesion barriers, advanced wound care products, ophthalmic solutions, and ear, nose, and throat treatments. Anika Therapeutics, Inc. was established in 1983 and is based in Bedford, Massachusetts.
ANIK Company Deck
ANIK Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call highlights clear commercial momentum (record international and commercial channel revenue), strong operational improvements (mid-60s gross margins, capacity expansions), and meaningful profitability gains (highest adjusted EBITDA since 2020) that supported upward guidance revisions. Key risks include FDA review uncertainty for Hyalofast, required CMC work for CINGAL, OEM revenue/order timing variability, modest U.S. pricing headwinds, and near-term cash conversion timing. Overall, positive execution and raised guidance outweigh the regulatory and timing headwinds.View all ANIK earnings summariesANIK Stock 12 Month Forecast
Average Price Target
$21.00
▼(-3.14% Downside)
Technical Analysis
Ownership Overview
5.00% Insiders
12.33% Mutual Funds
20.74% Other Institutional Investors
49.70% Public Companies and
Individual Investors